- Home
- CRDL vs ME Comparison
CRDL vs ME Comparison
Compare CRDL & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- ME
- Stock Information
- Founded
- CRDL 2017
- ME 2006
- Country
- CRDL Canada
- ME United States
- Employees
- CRDL N/A
- ME N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- ME Precision Instruments
- Sector
- CRDL Health Care
- ME Health Care
- Exchange
- CRDL Nasdaq
- ME Nasdaq
- Market Cap
- CRDL 125.7M
- ME 113.9M
- IPO Year
- CRDL N/A
- ME N/A
- Fundamental
- Price
- CRDL $1.28
- ME $3.27
- Analyst Decision
- CRDL Strong Buy
- ME Hold
- Analyst Count
- CRDL 3
- ME 1
- Target Price
- CRDL $9.00
- ME $9.40
- AVG Volume (30 Days)
- CRDL 391.0K
- ME 321.9K
- Earning Date
- CRDL 11-14-2024
- ME 02-05-2025
- Dividend Yield
- CRDL N/A
- ME N/A
- EPS Growth
- CRDL N/A
- ME N/A
- EPS
- CRDL N/A
- ME N/A
- Revenue
- CRDL N/A
- ME $193,260,000.00
- Revenue This Year
- CRDL N/A
- ME $21.93
- Revenue Next Year
- CRDL N/A
- ME $17.31
- P/E Ratio
- CRDL N/A
- ME N/A
- Revenue Growth
- CRDL N/A
- ME N/A
- 52 Week Low
- CRDL $0.79
- ME $2.66
- 52 Week High
- CRDL $3.12
- ME $19.34
- Technical
- Relative Strength Index (RSI)
- CRDL 26.78
- ME 41.70
- Support Level
- CRDL $1.27
- ME $3.03
- Resistance Level
- CRDL $1.46
- ME $3.50
- Average True Range (ATR)
- CRDL 0.10
- ME 0.33
- MACD
- CRDL -0.00
- ME 0.02
- Stochastic Oscillator
- CRDL 3.33
- ME 21.05
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.